| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/29/2007 | WO2007034881A1 Novel adenine compound |
| 03/29/2007 | WO2007034817A1 Novel adenine compound |
| 03/29/2007 | WO2007034784A1 Ctgf gene expression inhibitor |
| 03/29/2007 | WO2007034778A1 Prophylactic/therapeutic agent for sleep disorder |
| 03/29/2007 | WO2007034586A1 Photocatalytic titanium dioxide microparticle, dispersion liquid thereof and process for producing the same |
| 03/29/2007 | WO2007034527A2 snRNA GENE-LIKE TRANSCRIPTIONAL UNITS AND USES THEREOF |
| 03/29/2007 | WO2007034327A1 Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| 03/29/2007 | WO2007034272A1 Solid salt forms of a pyrrole substituted 2-indolinone |
| 03/29/2007 | WO2007034185A1 Purine compounds as hsp90 protein inhibitors for the treatment of cancer |
| 03/29/2007 | WO2007034173A1 Purine derivatives for the treatment of viral or allergic diseases and cancers |
| 03/29/2007 | WO2007034144A1 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| 03/29/2007 | WO2007034143A1 Quinazoline derivatives as anticancer agents |
| 03/29/2007 | WO2007034022A1 Composition for administration to mammals or humans |
| 03/29/2007 | WO2007033578A1 Metallo-fullerenols and its application in preparation of medicines for inhibiting the growth of tumour |
| 03/29/2007 | WO2007033434A1 Fulvestrant formulation |
| 03/29/2007 | WO2007012811A3 Prostate stem cell markers |
| 03/29/2007 | WO2007012614A3 Novel anti-igf-ir antibodies and uses thereof |
| 03/29/2007 | WO2007010516A3 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field |
| 03/29/2007 | WO2007010514A3 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field |
| 03/29/2007 | WO2007009721A3 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 03/29/2007 | WO2007008985A3 Kinase inhibitors |
| 03/29/2007 | WO2006138511A3 Use of hif 1alfa modulators for treatment of cancer |
| 03/29/2007 | WO2006127909A3 Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate |
| 03/29/2007 | WO2006127319A3 Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| 03/29/2007 | WO2006126177A3 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
| 03/29/2007 | WO2006125101A3 Raf inhibitor compounds and methods of use thereof |
| 03/29/2007 | WO2006124731A3 Compounds and compositions as protein kinase inhibitors |
| 03/29/2007 | WO2006108864A3 New nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof |
| 03/29/2007 | WO2006103568A3 NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF |
| 03/29/2007 | WO2006096491A3 Anti-ctla-4 antibody compositions |
| 03/29/2007 | WO2006072625A8 Anti-kir combination treatments and methods |
| 03/29/2007 | WO2002056916A8 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 03/29/2007 | US20070073077 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof |
| 03/29/2007 | US20070073043 Process for producing humanized chimera antibody |
| 03/29/2007 | US20070072916 Amino ceramide-like compounds and therapeutic methods of use |
| 03/29/2007 | US20070072865 Bicyclic piperazine compound and use thereof |
| 03/29/2007 | US20070072856 inhibitors of lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity; cancer screening therapy |
| 03/29/2007 | US20070072855 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers |
| 03/29/2007 | US20070072849 Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
| 03/29/2007 | US20070072841 Therapeutic compounds |
| 03/29/2007 | US20070072835 Method of preparing and use of prodrugs of betulinic acid derivatives |
| 03/29/2007 | US20070072818 Endothelial growth factors; antiischemic agents; neovascularization |
| 03/29/2007 | US20070072811 like antiinfective (bactericide, fungicide, parasiticide, viricide), and antiproliferative, antiinflammatory, and prokinetic agents; 1,2,3-triazole-oxazolidine-phenyl- derivatives; effective against strains of cells or organisms that have developed drug resistance; administering orally |
| 03/29/2007 | US20070072801 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 03/29/2007 | US20070072794 Novel genes and proteins encoded thereby |
| 03/29/2007 | US20070072263 DNA19355 polypeptide, a tumor necrosis factor homolog |
| 03/29/2007 | US20070072261 Nucleic acids encoding PAK5 polypeptidesm and methods of use thereof |
| 03/29/2007 | US20070072251 In vivo imaging using peptide derivatives |
| 03/29/2007 | US20070072236 Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors |
| 03/29/2007 | US20070072198 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 03/29/2007 | US20070071827 Polypeptides and Polynucleotides for Enhancing Immune Reactivity to HER-2 Protein |
| 03/29/2007 | US20070071771 Method for limiting the growth of cancer cells using an attenuated measles virus |
| 03/29/2007 | US20070071767 Polypeptides used for induction of cytotoxic T lymphocytes or activation of human leukocyte antigens (HLA), administered as anticarcinogenic vaccines; immunology |
| 03/29/2007 | US20070071749 Using cocktail comprising endothelial growth factor specific immunoglobulin and gemcitabine to treat and/or prevent pancreatic cancer |
| 03/29/2007 | US20070071748 Treatment with anti-vegf antibodies |
| 03/29/2007 | US20070071722 Nucleotide vaccine composition |
| 03/29/2007 | US20070071718 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of leukemia; immunotherapy |
| 03/29/2007 | US20070071674 Polynucleotides encoding novel isoforms of IGSF9 |
| 03/29/2007 | DE102005047691A1 Multiple-coated nano-particle, useful for transporting an active substance to a target cell, comprises an inner core, an inner sheath surrounding the core and an outer sheath surrounding the core and inner sheath |
| 03/29/2007 | CA2623490A1 Snrna gene-like transcriptional units and uses thereof |
| 03/29/2007 | CA2623345A1 Fulvestrant formulation |
| 03/29/2007 | CA2623293A1 Nanoparticles for targeted delivery of active agents |
| 03/29/2007 | CA2622997A1 A liposome composition to cause lysis of cells and pathogens |
| 03/29/2007 | CA2622870A1 Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| 03/29/2007 | CA2621720A1 Carbazole derivatives |
| 03/28/2007 | EP1767642A1 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof |
| 03/28/2007 | EP1767636A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 03/28/2007 | EP1767634A1 Novel galectin 8 modification protein and use thereof |
| 03/28/2007 | EP1767633A1 Novel polypeptide useful for diagnosis and treatment of cancer |
| 03/28/2007 | EP1767632A2 A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor |
| 03/28/2007 | EP1767627A1 Anti-perp antibody |
| 03/28/2007 | EP1767546A1 Angiogenesis-inhibiting chimeric protein and the use |
| 03/28/2007 | EP1767544A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 |
| 03/28/2007 | EP1767542A2 HLA-A2. 1 binding peptides and their uses |
| 03/28/2007 | EP1767541A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein |
| 03/28/2007 | EP1767533A1 N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor |
| 03/28/2007 | EP1767215A1 Isoflavones against radiation-induced mortality |
| 03/28/2007 | EP1767209A1 Neuroprotective drug |
| 03/28/2007 | EP1767199A2 Methods and compositions for treatment of cancer pain |
| 03/28/2007 | EP1767192A2 Cationic lipid compositions targeting angiogenic endothelial cells |
| 03/28/2007 | EP1766017A1 Tumor specific antibody |
| 03/28/2007 | EP1765984A2 Novel cancer cell lines and uses thereof |
| 03/28/2007 | EP1765853A2 O-linked glycosylation of peptides |
| 03/28/2007 | EP1765852A1 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member |
| 03/28/2007 | EP1765830A1 Mitotic kinesin inhibitors |
| 03/28/2007 | EP1765819A1 Azaindoles useful as inhibitors of protein kinases |
| 03/28/2007 | EP1765817A1 Thiazolinone unsubstituted quinolines |
| 03/28/2007 | EP1765813A1 Substituted indazoles, compositions containing same, preparation and use |
| 03/28/2007 | EP1765811A2 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents |
| 03/28/2007 | EP1765808A1 Bisarylurea derivatives useful for inhibiting chk1 |
| 03/28/2007 | EP1765790A1 Azine-carboxamides as anti-cancer agent |
| 03/28/2007 | EP1765789A1 N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer |
| 03/28/2007 | EP1765778A2 N-sulfonylcarboximidamide apoptosis promoters |
| 03/28/2007 | EP1765776A1 Novel tetrahydrocarbazole derivatives with improved biological action and improved solubility as ligands for g-protein coupled receptors (gpcrs) |
| 03/28/2007 | EP1765413A2 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 03/28/2007 | EP1765409A2 Conjugates of antibody and duocarmycin derivatives as antitumor agents |
| 03/28/2007 | EP1765399A1 Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma |
| 03/28/2007 | EP1765397A2 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
| 03/28/2007 | EP1765391A1 Bacterial compositions for the treatment of cancer |
| 03/28/2007 | EP1765385A1 Sustained release vaccine composition |